PT  - JOURNAL ARTICLE
AU  - Arijit A. Adhikari
AU  - Tom C. Seegar
AU  - Scott B. Ficarro
AU  - Megan D. McCurry
AU  - Deepti Ramachandran
AU  - Lina Yao
AU  - Snehal N. Chaudhari
AU  - Sula Ndousse-Fetter
AU  - Alexander S. Banks
AU  - Jarrod A. Marto
AU  - Stephen C. Blacklow
AU  - A. Sloan Devlin
TI  - Development of a Covalent Inhibitor of Gut Bacterial Bile Salt Hydrolases
AID  - 10.1101/640086
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 640086
4099  - http://biorxiv.org/content/early/2019/05/17/640086.short
4100  - http://biorxiv.org/content/early/2019/05/17/640086.full
AB  - Bile salt hydrolase (BSH) enzymes are widely expressed by human gut bacteria and catalyze the gateway reaction leading to secondary bile acid formation. Bile acids regulate key metabolic and immune processes by binding to host receptors. There is an unmet need for a potent tool to inhibit BSHs across all gut bacteria in order to study the effects of bile acids on host physiology. Here, we report the development of a covalent pan-inhibitor of gut bacterial BSH. From a rationally designed candidate library, we identified a lead compound bearing an alpha-fluoromethyl ketone warhead that modifies BSH at the catalytic cysteine residue. Strikingly, this inhibitor abolished BSH activity in conventional mouse feces. Mice gavaged with a single dose of this compound displayed decreased BSH activity and decreased deconjugated bile acid levels in feces. Our studies demonstrate the potential of a covalent BSH inhibitor to modulate bile acid composition in vivo.